Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
– Funding in place to meet next regulatory milestone
BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing anti-viral oral drugs to treat retroviruses like SARS-CoV-2 which cause COVID-19 and other viral diseases, announced that it has entered into a common stock purchase agreement with TRITON FUNDS LP for $500,000. The proceeds will help kickstart the dosage optimization study for mild to moderate COVID-19, which has already received the regulatory approval to proceed with dosing. TRITON FUNDS is the second institutional investor aligning its investment strategy with the lead institutional investor Walleye Capital, LLC which was founded in 2005 and now has $5 billion plus of assets under management.
Related news for (BIXT)
- Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During Strokes
- Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission
- Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
- Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
- Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens